Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

October 27, 2022

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
October 20, 2022

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate
October 10, 2022

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
October 4, 2022

Immunic to Participate in Scientific and Industry Conferences in October
September 20, 2022

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects
September 1, 2022

Immunic, Inc. to Participate in Investor Conferences in September
August 16, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium
August 4, 2022

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 2, 2022

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
July 28, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

Show per page